WRWilfrid Richer

Wilfrid Richer

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Wilfrid Richer has a total of 227 co-authors. Here are the top co-authors by number of shared publications:

  • Olivier Delattre

    INSERM U830, Diversity and Plasticity of Childhood Tumors Lab, PSL Research University, SIREDO Oncology Center, Institut Curie Research Center, Paris, France

    11 shared publications
  • Franck Bourdeaut

    Institut Curie, Paris, France

    8 shared publications
  • Gaelle Pierron

    Unité de Génétique Somatique, Service de Génétique, Hospital Group, Institut Curie, Paris, France

    6 shared publications
  • Julien Masliah-Planchon

    Paris-Sciences-Lettres Research University, Institut Curie, Laboratory of Somatic Genetics, Paris 75005, France

    5 shared publications
  • Camille Grison

    Institut Bergonie, Institut Curie, Unité de génétique somatique, Département de Biologie des Tumeurs, 26 rue d'Ulm, 75005 Paris, France

    4 shared publications
  • Catherine Miquel

    Hôpital Sainte-Anne, Service de neuropathologie; Paris France

    3 shared publications

Latest Publications

  • Single cell multi-OMICS analysis of Treg biology in cancer

    by Wilfrid Richer

    Analyses multi-OMIQUES à cellule unique de la biologie des Tregs dans le cancer: Les cellules T régulatrices (Treg) FOXP3+ jouent un rôle important dans l'inhibition de l'immunité contre le cancer, mais suppriment également l'auto-immunité. Le développement de thérapies ciblant les Tregs dans le cancer nécessite une caractérisation plus approfondie des populations de Tregs spécifiques aux tumeurs et des mécanismes qui conduisent à l'accumulation de Tregs dans les tumeurs. Pour explorer ces questions, nous avons réalisé un séquençage à cellule unique de l'ARN, du récepteur des cellules T (TCR) et des régions accessibles de la chromatine (ATAC) sur des cellules T CD4+ conventionnelles (Tconv) et des Tregs triés à partir de sang, de ganglions lymphatiques drainant les tumeurs (GL) et de tumeurs provenant des mêmes patients atteints de cancer du poumon non à petites cellules (CPNPC). Cela a révélé une grande diversité parmi les populations de Tregs et de Tconvs provenant des différents tissus. Nous identifions également une population spécifique de Tregs fonctionnels, associés à la tumeur et présentant une expansion clonale (FT-Treg) qui s'accumule dans les tumeurs et qui est enrichie en Tregs présentant une signature d'activation récente du TCR. Les gènes différentiellement exprimés entre les FT-Tregs et toutes les autres populations ont mis en évidence un ensemble de gènes spécifiquement enrichis dans les FT-Tregs qui peuvent être utilisés pour cibler les FT-Tregs tout en préservant les Tregs dans les tissus sains. Cette stratégie thérapeutique devrait réduire le risque d'auto-immunité indésirable. Un brevet protégeant ces résultats a été cédé sous licence à Egle therapeutics, une nouvelle start up liée à notre équipe. Nous décrivons également des modèles d'expansion clonale spécifiques aux tissus des différentes sous-populations de Tregs et de Tconvs effecteurs ; la migration entre la tumeur et les GLs de clones de Tregs et de Tconvs partageant les mêmes TCR, et la transition entre différents états de groupes de cellules T spécifiques, incluant la conversion Tconv/Treg. Les résultats de scATAC-seq permettent de mieux définir les différents groupes de cellules T et d'identifier une nouvelle population de Tregs "progéniteurs" enrichie dans le GL, qui alimente potentiellement les Tregs tissulaires et les cellules T présentant des caractéristiques folliculaires (Tfh). Dans l'ensemble, ces résultats enrichissent nos connaissances de base sur la diversité cellulaire, transcriptomique et épigénétique des cellules T CD4+ dans les tumeurs et en particulier dans les GLs, et fournissent de nouveaux candidats pour le ciblage thérapeutique des Tregs tumoraux chez les patients.

  • Open Access

    Common origin for effector and regulatory follicular and tissue-Adapted CD4+ T cells in Non-Small Cell Lung Cancer

    by Jimena Tosello Boari, Wilfrid Richer, Yoann Missolo-Koussou, Elisa Bonnin, Sebastien Lemoine, Marco Antônio Pretti, Rodrigo Nalio Ramos, Jordan Denizeau, Sylvain Baulande, Mylène Bohec, et al.

    Tumor-invaded lymph nodes (LNs) serve as critical hubs for anti-tumor immunity, yet their role in orchestrating immune responses remains poorly understood. Using integrated single-cell RNA sequencing, T cell receptor sequencing, and chromatin accessibility profiling, we analyzed CD4+ T cells from matched blood, tumor-invaded LNs, and tumors of treatment-naïve non-small cell lung cancer patients. We identified distinct immunological landscapes across these compartments. Compared to blood, tumor-invaded LNs and tumors were enriched for follicular regulatory T cells (Treg-Tfr), conventional T cell subsets with Tfh-like characteristics (Tconv-Tfh and Tconv-CXCL13), and tissue-resident memory Tregs (Treg-Trm). These populations share a BATF-dependent transcriptional program that governs T-cell activation and tissue adaptation, while simultaneously engaging distinct, subset-specific regulatory networks. Integrative TCR-RNA analysis revealed that tumor-reactive, neoantigen-specific T cell clones were enriched within these subsets and demonstrated extensive LN-tumor clonal sharing, indicating active recirculation between compartments. Through clonal coupling analysis and trajectory inference, we uncovered that Treg-Tfr cells function as multipotent progenitors that bifurcate into tissue-resident Treg-Trm or into ex-Tregs adopting a Tfh-like CXCL13+ ewector phenotype. Remarkably, follicular CD4+ T subsets from LNs and tumor were transcriptionally and epigenetically similar and localized to analogous germinal center niches. These findings establish tumor-invaded LNs as functional extensions of the tumor microenvironment that generate and maintain tumor-reactive CD4+ lineages. The identification of tissue-resident Treg-Tfr plasticity reveals a critical developmental checkpoint that could be therapeutically targeted to redirect immunosuppressive programs toward anti-tumor ewector responses.


  • Open Access

    CD39 + conventional CD4 + T cells with exhaustion traits and cytotoxic potential infiltrate tumors and expand upon CTLA-4 blockade

    by Sabrina N. Bossio, Carolina Abrate, Jimena Tosello Boari, Constanza Rodriguez, Fernando P. Canale, María C. Ramello, Wilfrid Richer, Dario Rocha, Christine Sedlik, Anne Vincent-Salomon, et al.

    Background: Conventional CD4 + T (Tconv) lymphocytes play important roles in tumor immunity; however, their contribution to tumor elimination remains poorly understood. Methods: Here we describe a subset of Tconv cells characterized by the expression of CD39. The phenotype, the effector function and transcriptional profile of tumor-infiltrating CD39 + Tconv lymphocytes from different mouse cancer models and breast cancer patients were studied by multiparametric flow cytometry and RNA sequencing. The impact of the in vivo CTLA-4 blockade on the tumor-infiltrating CD39 + Tconv population was assessed in mice grafted with the immunogenic MC38 colorectal tumor. Overall survival was evaluated in a cohort of patients from the TCGA consortium. Results: In mouse cancer models, we observed that CD39 + Tconv cells accumulated in tumors as they grew but were absent in lymphoid organs. Compared to tumor CD39 − counterparts, CD39 + Tconv cells exhibited a cytotoxic and exhausted signature at the transcriptomic level, confirmed by high protein expression of inhibitory receptors and transcription factors related to the exhaustion phenotype. Additionally, CD39 + Tconv cells showed increased production of IFN gamma, granzyme B, perforin and CD107a expression, but reduced production of TNF. In vivo CTLA-4 blockade induced the expansion of tumor CD39 + Tconv cells, which maintained their cytotoxic and exhausted features. In breast cancer patients, CD39 + Tconv cells were found in tumors and in metastatic lymph nodes but were less frequent in adjacent non-tumoral mammary tissue and not detected in non-metastatic lymph nodes and blood. Human tumor CD39 + Tconv cells constituted a heterogeneous cell population with features of exhaustion, impaired TNF production, and high expression of inhibitory receptors and CD107a. We found that high CD4 and ENTPD1 (CD39) gene expression in human tumor tissues correlated with a higher overall survival rate in breast cancer patients. Conclusions: We found that CD39 acts as a biomarker of Tconv cells with characteristics of both exhaustion and cytotoxic potential. CTLA-4 blockade expands CD39 + CD4 + T cells which may contribute to the reduction of tumor development. Discovering the role of CD39-expressing CD4 + T cells in the tumor microenvironment should help design new strategies to manipulate them and improve the efficacy of current immunotherapies.

  • Open Access

    Evolution of synchronous bilateral breast cancers provide insights into interactions between host, tumor and immunity

    by Anne-Sophie Hamy, Judith Abecassis, Lauren Darrigues, Cecile Laurent, François Zaccarini, Benjamin Sadacca, Myriam Delomenie, Enora Laas, Odette Mariani, Thanh Lam, et al.

    Synchronous bilateral breast cancer (sBBC) occurs after both breasts have been affected by the same germline genetics, reproductive life factors and environmental exposures for decades. It represents an opportunity to decipher the complex interplay between host, tumor, immune system and response to neoadjuvant chemotherapy (NAC). On a cohort of 17575 BCs treated between 2005 and 2012, sBBCs (n=404) were associated with less aggressive proliferative patterns and higher rates of luminal breast cancers (BCs) when compared with unilateral BCs (n=17171). The left and right tumors were concordant for the majority of clinical and pathological features. Tumor pairs of concordant BC subtype were more frequent than pairs of discordant BC subtype, with notably a particularly high frequency of pairs of luminal BCs. Intriguingly, both the levels of tumor infiltrating lymphocytes (TILs) and the response to NAC were modified by the subtype of the contralateral tumors. Whole exome sequencing and RNAseq analyses revealed that left and right tumors were independent from a somatic mutation and transcriptomic point of view, while primary tumors (PT) before NAC and specimens with residual disease (RD) after NAC were more closely related. The analysis of the TCR repertoire identified very little overlap between patients, while common clones were shared in bilateral tumors within each patient. After NAC, the TCR repertoire of RD was enriched and expanded with clones edited by the contralateral PT.

  • Open Access

    High-Throughput Drug Screening Identifies Pazopanib and Clofilium Tosylate as Promising Treatments for Malignant Rhabdoid Tumors

    by Céline Chauvin, Amaury Leruste, Arnault Tauziede-Espariat, Mamy Andrianteranagna, Didier Surdez, Aurianne Lescure, Zhi-Yan Han, Elodie Anthony, Wilfrid Richer, Sylvain Baulande, et al.


  • Open Access

    Embryonic signature distinguishes pediatric and adult rhabdoid tumors from other SMARCB1-deficient cancers

    by Wilfrid Richer, Julien Masliah-Planchon, Nathalie Clement, Irene Jimenez, Laetitia Maillot, David Gentien, Benoît Albaud, Walid Chemlali, Christine Galant, Frederique Larousserie, et al.

    Oncotarget | https://doi.org/10.18632/oncotarget.15939 Wilfrid Richer, Julien Masliah-Planchon, Nathalie Clement, Irene Jimenez, Laetitia Maillot, David Gentien, Benoît Albaud, Walid Chemlali, Christine Galant,... Embryonic signature distinguishes pediatric and adult rhabdoid tumors from other SMARCB1-deficient cancers


  • Open Access

    Genomic Copy Number Profiling Using Circulating Free Tumor DNA Highlights Heterogeneity in Neuroblastoma

    by Mathieu Chicard, Sandrine Boyault, Leo Colmet Daage, Wilfrid Richer, David Gentien, Gaelle Pierron, Eve Lapouble, Angela Bellini, Nathalie Clement, Isabelle Iacono, et al.

    Purpose: The tumor genomic copy number profile is of prognostic significance in neuroblastoma patients. We have studied the genomic copy number profile of cell-free DNA (cfDNA) and compared this with primary tumor arrayCGH (aCGH) at diagnosis. Experimental Design: In 70 patients, cfDNA genomic copy number profiling was performed using the OncoScan platform. The profiles were classified according to the overall pattern, including numerical chromosome alterations (NCA), segmental chromosome alterations (SCA), and MYCN amplification (MNA). Results: Interpretable and dynamic cfDNA profiles were obtained in 66 of 70 and 52 of 70 cases, respectively. An overall identical genomic profile between tumor aCGH and cfDNA was observed in 47 cases (3 NCAs, 22 SCAs, 22 MNAs). In one case, cfDNA showed an additional SCA not detected by tumor aCGH. In 4 of 8 cases with a silent tumor aCGH profile, cfDNA analysis revealed a dynamic profile (3 SCAs, 1 NCA). In 14 cases, cfDNA analysis did not reveal any copy number changes. A total of 378 breakpoints common to the primary tumor and cfDNA of any given patient were identified, 27 breakpoints were seen by tumor aCGH, and 54 breakpoints were seen in cfDNA only, including two cases with interstitial IGFR1 gains and two alterations targeting TERT. Conclusions: These results demonstrate the feasibility of cfDNA copy number profiling in neuroblastoma patients, with a concordance of the overall genomic profile in aCGH and cfDNA dynamic cases of 97% and a sensitivity of 77%, respectively. Furthermore, neuroblastoma heterogeneity is highlighted, suggesting that cfDNA might reflect genetic alterations of more aggressive cell clones. Clin Cancer Res; 22(22); 5564–73. ©2016 AACR. See related commentary by Janku and Kurzrock, p. 5400


  • Balanced Translocations Disrupting SMARCB1 Are Hallmark Recurrent Genetic Alterations in Renal Medullary Carcinomas

    by Julien Calderaro, Julien Masliah-Planchon, Wilfrid Richer, Laetitia Maillot, Pascale Maille, Ludovic Mansuy, Claire Bastien, Alexandre de la Taille, Hélène Boussion, Cécile Charpy, et al.


  • Open Access

    The occurrence of intracranial rhabdoid tumours in mice depends on temporal control of Smarcb1 inactivation

    by Zhi-Yan Han, Wilfrid Richer, Paul Fréneaux, Céline Chauvin, Carlo Lucchesi, Delphine Guillemot, Camille Grison, Delphine Lequin, Gaelle Pierron, Julien Masliah-Planchon, et al.

    Rhabdoid tumours (RTs) are highly aggressive tumours of infancy, frequently localized in the central nervous system (CNS) where they are termed atypical teratoid/rhabdoid tumours (AT/RTs) and characterized by bi-allelic inactivation of the SMARCB1 tumour suppressor gene. In this study, by temporal control of tamoxifen injection in Smarcb1flox/flox;Rosa26-CreERT2 mice, we explore the phenotypes associated with Smarcb1 inactivation at different developmental stages. Injection before E6, at birth or at 2 months of age recapitulates previously described phenotypes including embryonic lethality, hepatic toxicity or development of T-cell lymphomas, respectively. Injection between E6 and E10 leads to high penetrance tumours, mainly intra-cranial, with short delays (median: 3 months). These tumours demonstrate anatomical, morphological and gene expression profiles consistent with those of human AT/RTs. Moreover, intra- and inter-species comparisons of tumours reveal that human and mouse RTs can be split into different entities that may underline the variety of RT cells of origin.


  • Top Cited Papers

    SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomas

    by Francois Le Loarer, Sarah Watson, Gaelle Pierron, Vincent Thomas de Montpreville, Stelly Ballet, Nelly Firmin, Aurelie Auguste, Daniel Pissaloux, Sandrine Boyault, Sandrine Paindavoine, et al.

    While investigating cohorts of unclassified sarcomas by RNA sequencing, we identified 19 cases with inactivation of SMARCA4, which encodes an ATPase subunit of BAF chromatin-remodeling complexes1,2. Clinically, the cases were all strikingly similar, presenting as compressive mediastino-pulmonary masses in 30- to 35-year-old adults with a median survival time of 7 months. To help define the nosological relationships of these tumors, we compared their transcriptomic profiles with those of SMARCA4-mutated small-cell carcinomas of the ovary, hypercalcemic type (SCCOHTs)3,4,5, SMARCB1-inactivated malignant rhabdoid tumors6 (MRTs) and lung carcinomas (of which 10% display SMARCA4 mutations7). Gene profiling analyses demonstrated that these tumors were distinct from lung carcinomas but related to MRTs and SCCOHTs. Transcriptome analyses, further validated by immunohistochemistry, highlighted strong expression of SOX2, a marker that supports the differential diagnosis of these tumors from SMARCA4-deficient lung carcinomas. The prospective recruitment of cases confirmed this new category of 'SMARCA4-deficient thoracic sarcomas' as readily recognizable in clinical practice, providing opportunities to tailor their therapeutic management.